Intraperitoneal bispecific antibody (HEA125XOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma

International Journal of Cancer

Volumn 101, Issue 2, 2002, Pages 183-189

  Marmé, Alexander ^a   Strauß, Gudrun ^b   Bastert, Gunther ^a   Grischke, Eva Maria ^a   Moldenhauer, Gerhard ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antibody treatment; Immunotherapy; Malignant ascites; Ovarian carcinoma; Vascular permeability

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC ANTIBODY HEA125XOKT3; CA 125 ANTIGEN; OKT 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; ASCITES; ASCITES FLUID; BLOOD VESSEL PERMEABILITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOLYSIS; DOWN REGULATION; ECZEMA; FEMALE; FEVER; HUMAN; IN VITRO STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

ANTIBODIES, BISPECIFIC; ASCITES; CELL DIVISION; FEMALE; FLOW CYTOMETRY; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS;

EID: 0037056226     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10562     Document Type: Article

References (33)

1. Cancer statistics, 2000
2. Current initial therapy of Stage III and IV ovarian cancer: Challenges for managed care
3. Biological therapy of ovarian cancer: Current directions
4. Ovarian cancer chemotherapy
5. Complications from intraperitoneal radioactive phosphorus in ovarian malignancies
6. Effect of intraperitoneal recombinant human tumor necrosis factor α on malignant ascites
7. Bispecific antibodies in cancer therapy
8. Of mice and men: Hybridoma and recombinant antibodies
9. Immunotherapeutic perspective for bispecific antibodies
10. SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2
11. The biology of the 17-1A antigen (Ep-CAM)
12. Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker
13. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues
14. Without prior stimulation, tumor associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3
15. Local antitumor treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells
16. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody
17. Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28
18. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma
19. Human immune response to monoclonal antibodies
20. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells
21. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes
22. Level of anti-mouse-antibody response induced by bispecific monoclonal antibody OC/TR in ovarian carcinoma patients is associated with longer survival
23. The antiidiotype vaccines for immunotherapy
24. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA 125: Immune responses and survival in palliative treatment
25. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotype antibody BEC2 plus Bacillus Calmette-Guerin
26. Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets
27. Role of vascular endothelial growth factor in ovarian cancer
28. Macrophage-induced angiogenesis is mediated by tumor necrosis factor-alpha
29. Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo
30. Tumor necrosis factor α-induced angiogenesis depends on in situ platelet-activating factor biosynthesis
31. Induction of vascular endothelial growth factor by tumor necrosis factor-α in human glioma cells
32. VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence
33. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation